Teva Pharmaceuticals has been developing and producing medicines to help improve people’s lives for more than a century. We are committed to being a global leader in generic and specialty medicines with a portfolio of 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day. They are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com. Please …

Sectors: Pharmaceutical

Visionary ventures IP Group accelerates the impact of science for a better future. As the most active UK based, early-stage science investor, we develop and support some of the world’s most exciting businesses in deeptech, life sciences and cleantech (led by Kiko Ventures). Through Parkwalk, the UK's largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, First Light Fusion, Hysata, and Oxbotica. IP …

Helping to commercialise research from the University of Cambridge for the benefit of society worldwide. Cambridge Enterprise is the commercialisation arm of the University of Cambridge. At Cambridge Enterprise, we help University of Cambridge members create beneficial impact from their research and expertise that can change the world, through academic consultancy, intellectual property management, development and licensing, venture building, venture funding and convening and connecting the wider Cambridge innovation ecosystem. Our success is measured in the success of our University partners as they bring their work to market, be it ground-breaking stem cell research, critical suspension technology used in Formula …

Sectors: Startup accelerator & VC

We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com. Community Guidelines: bit.ly/2MgAcio Pharmaceutical, Biopharmaceutical, Innovation, Research and development, and Global business

Sectors: Pharmaceutical

Get more done with faster, more productive AI and analytics from the most trusted analytics partner on the planet. Get more done with faster, more productive AI and analytics from the most trusted analytics partner on the planet. Produce answers as fast as the world produces data with SAS. With over forty years of analytics innovation, SAS has been giving customers around the world THE POWER TO KNOW®. SAS, BI, Data Mining, Analytics, Business Analytics, Predictive Analytics, Statistics, Customer Intelligence, Enterprise Risk Management, AI, artificial intelligence, speed, productivity, SAS Viya, and cloud

Sectors: IT services

The venture builder for the climate emergency. We are Carbon13, the venture builder for the climate emergency. We are now working to create ~200 ventures that have the capacity to reduce CO2e emissions by 400 million tonnes. 32 innovative carbon emissions-mitigating startups have been launched so far by Cohorts 1-3 of Carbon13’s Venture Builder for the Climate Emergency, across sectors such as agriculture, renewable energy, the built environment, food, and materials. Cohort 4 began their entrepreneurial journey in September and applications are open now for Cambridge Cohort 5 along with applications for Berlin Cohort 1. After an oversubscribed Carbon13 SEIS …